EcoR1 Capital LLC acquired a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the first quarter, Holdings Channel reports. The institutional investor acquired 794,969 shares of the biotechnology company’s stock, valued at approximately $13,729,000. CytomX Therapeutics comprises about 3.5% of EcoR1 Capital LLC’s investment portfolio, making the stock its 9th largest position.
A number of other hedge funds have also modified their holdings of the company. Perceptive Advisors LLC acquired a new stake in shares of CytomX Therapeutics during the fourth quarter valued at approximately $10,152,000. JPMorgan Chase & Co. increased its stake in shares of CytomX Therapeutics by 551.5% in the first quarter. JPMorgan Chase & Co. now owns 185,778 shares of the biotechnology company’s stock valued at $3,208,000 after buying an additional 157,261 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in shares of CytomX Therapeutics during the first quarter valued at approximately $2,591,000. Renaissance Technologies LLC increased its stake in shares of CytomX Therapeutics by 157.5% in the first quarter. Renaissance Technologies LLC now owns 234,800 shares of the biotechnology company’s stock valued at $4,055,000 after buying an additional 143,600 shares during the last quarter. Finally, Monashee Investment Management LLC acquired a new stake in shares of CytomX Therapeutics during the first quarter valued at approximately $798,000. 52.45% of the stock is currently owned by institutional investors and hedge funds.
CytomX Therapeutics, Inc. (NASDAQ CTMX) traded up 0.89% during mid-day trading on Friday, hitting $13.60. The company’s stock had a trading volume of 197,870 shares. The firm’s market cap is $499.79 million. The firm has a 50 day moving average of $14.53 and a 200-day moving average of $13.63. CytomX Therapeutics, Inc. has a 52-week low of $9.10 and a 52-week high of $20.02.
CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Friday, May 5th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.32. CytomX Therapeutics had a negative net margin of 208.92% and a negative return on equity of 59.65%. The company had revenue of $11.65 million for the quarter, compared to analyst estimates of $2.10 million. On average, equities research analysts expect that CytomX Therapeutics, Inc. will post ($1.46) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was first reported by sleekmoney and is the sole property of of sleekmoney. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://sleekmoney.com/ecor1-capital-llc-invests-13-73-million-in-cytomx-therapeutics-inc-ctmx/1916408.html.
Several analysts recently commented on CTMX shares. Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a research note on Wednesday, May 3rd. HC Wainwright started coverage on CytomX Therapeutics in a research note on Monday, March 27th. They set a “buy” rating and a $24.00 price objective on the stock. ValuEngine downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. Nomura started coverage on CytomX Therapeutics in a research note on Wednesday, March 1st. They issued a “buy” rating on the stock. Finally, Instinet lifted their price target on CytomX Therapeutics from $21.00 to $32.00 and gave the company a “sell” rating in a research note on Monday, March 20th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. CytomX Therapeutics has an average rating of “Hold” and an average price target of $24.50.
In related news, major shareholder Rock Ventures Lp Third sold 1,650,000 shares of the company’s stock in a transaction dated Monday, March 27th. The shares were sold at an average price of $17.39, for a total value of $28,693,500.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Sean A. Mccarthy sold 4,781 shares of the company’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $15.70, for a total transaction of $75,061.70. Following the completion of the sale, the insider now owns 6,760 shares in the company, valued at approximately $106,132. The disclosure for this sale can be found here. Insiders sold a total of 1,728,860 shares of company stock worth $30,109,014 in the last 90 days. 4.70% of the stock is currently owned by company insiders.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/ecor1-capital-llc-invests-13-73-million-in-cytomx-therapeutics-inc-ctmx/1916408.html
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.